Abstract
Background
Cerebrospinal fluid (CSF) biomarkers have been studied to differentiate between patients with ALS and neurological controls, but not in comparison to clinically more relevant disorders mimicking ALS.
Methods
In this retrospective study, CSF concentrations of various brain-specific proteins were analyzed in patients with ALS (n = 32) and ALS-mimic disorders (n = 26).
Results
CSF concentrations of neurofilament light (NFL) and heavy chain (NFHp35), but not other brain-specific proteins, were significantly higher in patients with ALS than in patients with an ALS-mimic disorder, however with maximum sensitivity or specificity of 80 %. The mean CSF level of NFHp35 was 781 ng/L in the ALS group vs. 338 ng/L in the ALSmimic disorders group and for NFL the mean CSF levels were 62 ng/L vs. 24 ng/L.
Conclusion
Although CSF concentrations of NFL and NFHp35 are higher in patients with ALS, the diagnostic accuracy for differentiating ALS from ALS-mimic disorders seems insufficient. Our results suggest that, in the clinical work-up of patients suspected of ALS, application of CSF analysis alone is limited but may have potential in combination with other clinical and electrophysiological markers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdo WF, Bloem BR, van Geel WJ, Esselink RA, Verbeek MM (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson‘s disease. Neurobiol Aging 28:742–747
Abdo WF, De Jong D, Hendriks JC, Horstink MW, Kremer BP, Bloem BR, Verbeek MM (2004) Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson‘s disease. Mov Disord 19:571–579
Abdo WF, van de Warrenburg BP, Munneke M, van Geel WJ, Bloem BR, Kremer HP, Verbeek MM (2006) CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 67:474–479
Beems T, Simons KS, van Geel WJ, De Reus HP, Vos PE, Verbeek MM (2003) Serum- and CSF-concentrations of brain specific proteins in hydrocephalus. Acta Neurochir (Wien) 145:37–43
Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H (2006) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66:852–856
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299
Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, de BF, Zurdo JM, Alonso H, Puertas I, Barcenilla B, Sayed Y, Cabrera-Valdivia F (2005) Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 111:114–117
Julien JP, Kriz J (2006) Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762:1013–1024
Makki AA, Benatar M (2007) The electromyographic diagnosis of amyotrophic lateral sclerosis: does the evidence support the El Escorial criteria? Muscle Nerve 35:614–619
Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987:25–31
Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ (2003) A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 278:179–190
Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ (2004) An ELISA for glial fibrillary acidic protein. J Immunol Methods 287:169–177
Shaw PJ (2005) Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry 76:1046–1057
Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, Vanmechelen E, Blennow K (2002) Decreased CSF-beta-amyloid 42 in Alzheimer‘s disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 13:112–118
Strong MJ, Kesavapany S, Pant HC (2005) The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 64:649–664
Sussmuth SD, Tumani H, Ecker D, Ludolph AC (2003) Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 353:57–60
van Geel WJ, Rosengren LE, Verbeek MM (2005) An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 296:179–185
Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel WJ, De Reus HP, Biert J, Verbeek MM (2004) Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 62:1303–1310
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reijn, T.S., Abdo, W.F., Schelhaas, H.J. et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 256, 615–619 (2009). https://doi.org/10.1007/s00415-009-0131-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-0131-z